These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16083461)

  • 1. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines.
    Aronoff GM; Brennan MJ; Pritchard DD; Ginsberg B
    Pain Med; 2005; 6(4):305-14. PubMed ID: 16083461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
    Gordon DB
    Oncol Nurs Forum; 2006 Nov; 33(2):257-64. PubMed ID: 16518441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
    Borgbjerg FM; Rosenberg J
    Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study.
    Jacobsen R; Møldrup C; Christrup L
    Pain Med; 2009 Nov; 10(8):1442-51. PubMed ID: 19793344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of oral transmucosal fentanyl citrate during high-dose-rate gynecologic brachytherapy.
    Proud C
    Clin J Oncol Nurs; 2007 Aug; 11(4):561-7. PubMed ID: 17723969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries.
    Mahar PJ; Rana JA; Kennedy CS; Christopher NC
    Pediatr Emerg Care; 2007 Aug; 23(8):544-8. PubMed ID: 17726413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
    Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
    Parikh N; Goskonda V; Chavan A; Dillaha L
    Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ).
    Taylor DR; Webster LR; Chun SY; Reinking J; Stegman M; Shoemaker S; Fortner B
    Pain Med; 2007 Apr; 8(3):281-8. PubMed ID: 17371416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Vlahos L; Tsiatas ML
    Drug Deliv; 2006; 13(4):269-76. PubMed ID: 16766468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
    Jandhyala R; Fullarton JR; Bennett MI
    J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails.
    Prescrire Int; 2002 Aug; 11(60):106-7. PubMed ID: 12199262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    J Opioid Manag; 2005; 1(1):36-40. PubMed ID: 17315410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield.
    Wedmore IS; Kotwal RS; McManus JG; Pennardt A; Talbot TS; Fowler M; McGhee L
    J Trauma Acute Care Surg; 2012 Dec; 73(6 Suppl 5):S490-5. PubMed ID: 23192075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
    Christie JM; Simmonds M; Patt R; Coluzzi P; Busch MA; Nordbrock E; Portenoy RK
    J Clin Oncol; 1998 Oct; 16(10):3238-45. PubMed ID: 9779697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate.
    Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
    J Clin Pharmacol; 2007 Mar; 47(3):343-50. PubMed ID: 17322146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal therapeutic fentanyl-system (TTS-F).
    Mystakidou K; Katsouda E; Tsilika E; Parpa E; Vlahos L
    In Vivo; 2004; 18(5):633-42. PubMed ID: 15523905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral transmucosal fentanyl citrate: a novel analgesic agent for use in retinal photocoagulation.
    Hillier RJ; Aboud A; Thind G; Clark DI
    Retina; 2009; 29(10):1506-12. PubMed ID: 19696704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.